NSCLC

Many patients diagnosed with early-stage NSCLC face a significant risk of recurrent disease and poor long-term outcome.^11,12

For example, patients with ALK-positive NSCLC typically have a worse prognosis in the early stages than those with EGFR mutations¹³

Despite a similar prevalence of ALK mutations among Black and White populations, racial disparities exist in biomarker testing.^14,15

Black patients with nonsquamous NSCLC are significantly less likely to undergo NGS testing at any point after their diagnosis¹⁵

Early testing in certain patients for ALK and EGFR mutations, as well as PD-L1 expression, in patients with NSCLC can help identify targeted therapy options.^1,3,16

Learn more about lung cancer